AstraZeneca approaches Gilead about potential merger
AstraZeneca, valued at $140 billion, is the U.K.s biggest drugmaker by market capitalization and has developed treatments for conditions from cancer to cardiovascular disease. Gilead, worth $96 billion at Fridays close, is the creator of a drug thats received U.S. approval for use with coronavirus patients.